Vivo Capital LLC boosted its stake in shares of Biopharmx Corp (NASDAQ:BPMX) by 10.0% during the second quarter, Holdings Channel reports. The firm owned 14,096,338 shares of the company’s stock after buying an additional 1,282,052 shares during the period. Biopharmx Corp makes up 1.7% of Vivo Capital LLC’s holdings, making the stock its 13th largest position. Vivo Capital LLC owned about 0.19% of Biopharmx Corp worth $6,752,000 as of its most recent SEC filing.

Biopharmx Corp (NASDAQ:BPMX) opened at 0.27 on Friday. The firm has a 50-day moving average of $0.40 and a 200 day moving average of $0.50. Biopharmx Corp has a 52 week low of $0.19 and a 52 week high of $1.22. The stock’s market capitalization is $20.01 million.

Biopharmx Corp (NASDAQ:BPMX) last released its quarterly earnings results on Tuesday, June 13th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%. On average, analysts anticipate that Biopharmx Corp will post ($0.31) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Vivo Capital LLC Has $6.75 Million Position in Biopharmx Corp (NASDAQ:BPMX)” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/13/vivo-capital-llc-has-6-75-million-position-in-biopharmx-corp-nasdaqbpmx.html.

Several analysts recently weighed in on the stock. Maxim Group reaffirmed a “buy” rating and issued a $3.00 target price on shares of Biopharmx Corp in a report on Thursday, May 4th. Roth Capital set a $3.00 target price on shares of Biopharmx Corp and gave the company a “buy” rating in a report on Saturday, June 3rd. Finally, HC Wainwright set a $3.00 target price on shares of Biopharmx Corp and gave the company a “buy” rating in a report on Thursday, June 15th.

In related news, major shareholder Franklin Resources Inc purchased 250,000 shares of Biopharmx Corp stock in a transaction that occurred on Tuesday, August 1st. The shares were purchased at an average cost of $0.34 per share, with a total value of $85,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Want to see what other hedge funds are holding BPMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biopharmx Corp (NASDAQ:BPMX).

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.